Roche HoldingsCH0012032048ROGROG
![Roche Holdings logo](https://static.getquin.com/logos/CH0012032048.png)
Financials
Market Cap
$227.53B5Y beta
0.70EPS (TTM)
$15.85Free Float
719.54MP/E ratio (TTM)
17.51Revenue (TTM)
$65.07BEBITDA (TTM)
$24.39BFree Cashflow (TTM)
$3.90BPricing
Analyst Ratings
The price target is $301.39 and the stock is covered by 23 analysts.
Buy
9
Hold
9
Sell
5
Information
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.